Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: RARA 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
2 Adipocytokine signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
3 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
4 African trypanosomiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
5 African trypanosomiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
6 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
7 Alcoholic liver disease 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
8 Alcoholic liver disease 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
9 Alcoholic liver disease 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
10 Alcoholic liver disease 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
11 Alcoholic liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
12 Allograft rejection 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
13 Allograft rejection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
14 Allograft rejection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
15 Alzheimer disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
16 Alzheimer disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
17 Amoebiasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
18 Amoebiasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
19 Amphetamine addiction 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
20 AMPK signaling pathway 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
21 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
22 AMPK signaling pathway 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
23 Amyotrophic lateral sclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
24 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
25 Antifolate resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
26 Antigen processing and presentation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
27 Apoptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
28 Arachidonic acid metabolism 💬
 1件: ALOX5 💬 D00414 💬 Zileuton 3件: 85, 160, 164 💬
29 Asthma 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
30 Autoimmune thyroid disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
31 Axon guidance 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
32 B cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
33 Bile secretion 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
34 Bile secretion 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
35 Bile secretion 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
36 C-type lectin receptor signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
37 C-type lectin receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
38 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
39 Calcium signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
40 cAMP signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
41 Cell adhesion molecules 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
42 Cellular senescence 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
43 cGMP-PKG signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
44 Chagas disease 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
45 Chagas disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
46 Chemical carcinogenesis - receptor activation 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
47 Coronavirus disease - COVID-19 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
48 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
49 Cytokine-cytokine receptor interaction 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
50 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
51 Cytokine-cytokine receptor interaction 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
52 Cytokine-cytokine receptor interaction 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
53 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
54 Diabetic cardiomyopathy 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
55 Dilated cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
56 Dopaminergic synapse 💬
 3件: PPP3CA, PPP3CB, PPP3CC 💬 D05480 💬 Pimecrolimus 1件: 160 💬
57 Epstein-Barr virus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
58 Estrogen signaling pathway 💬
 1件: RARA 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
59 Fc epsilon RI signaling pathway 💬
 1件: ALOX5 💬 D00414 💬 Zileuton 3件: 85, 160, 164 💬
60 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
61 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
62 Gastric cancer 💬
 1件: RARB 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
63 Glucagon signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
64 Glucagon signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
65 Glutamatergic synapse 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
66 Graft-versus-host disease 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
67 Graft-versus-host disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
68 Hematopoietic cell lineage 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
69 Hematopoietic cell lineage 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
70 Hepatitis B 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
71 Hepatitis C 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
72 Hepatitis C 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
73 Herpes simplex virus 1 infection 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
74 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
75 Human cytomegalovirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
76 Human cytomegalovirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
77 Human immunodeficiency virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
78 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
79 Human papillomavirus infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
80 Human T-cell leukemia virus 1 infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
81 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
82 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
83 IL-17 signaling pathway 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
84 IL-17 signaling pathway 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
85 IL-17 signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
86 Inflammatory bowel disease 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
87 Inflammatory bowel disease 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
88 Inflammatory bowel disease 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
89 Inflammatory bowel disease 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
90 Inflammatory bowel disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
91 Influenza A 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
92 Influenza A 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
93 Insulin resistance 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
94 Insulin resistance 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
95 Intestinal immune network for IgA production 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
96 JAK-STAT signaling pathway 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
97 JAK-STAT signaling pathway 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
98 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
99 Kaposi sarcoma-associated herpesvirus infection 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
100 Legionellosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
101 Legionellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
102 Leishmaniasis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
103 Leishmaniasis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
104 Lipid and atherosclerosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
105 Lipid and atherosclerosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
106 Lipid and atherosclerosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
107 Long-term potentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
108 Malaria 💬
 1件: IL12A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
109 Malaria 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
110 MAPK signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
111 MAPK signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
112 Measles 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
113 Metabolic pathways 💬
 1件: ALOX5 💬 D00414 💬 Zileuton 3件: 85, 160, 164 💬
114 Metabolic pathways 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
115 Metabolic pathways 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
116 Metabolic pathways 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
117 mTOR signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
118 Natural killer cell mediated cytotoxicity 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
119 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
120 Necroptosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
121 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
122 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
123 Non-alcoholic fatty liver disease 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
124 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
125 Non-small cell lung cancer 💬
 1件: RARB 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
126 Oocyte meiosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
127 Osteoclast differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
128 Osteoclast differentiation 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
129 Ovarian steroidogenesis 💬
 1件: ALOX5 💬 D00414 💬 Zileuton 3件: 85, 160, 164 💬
130 Oxytocin signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
131 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
132 Pathways in cancer 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
133 Pathways in cancer 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
134 Pathways in cancer 💬
 2件: RARA, RARB 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
135 Pathways of neurodegeneration - multiple diseases 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
136 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
137 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
138 Pertussis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
139 Pertussis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
140 PI3K-Akt signaling pathway 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
141 PPAR signaling pathway 💬
 1件: PPARA 💬 D01366 💬 Bezafibrate 7件: 20, 93, 94, 160, 296, 316, 324 💬
142 Prion disease 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
143 Prion disease 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
144 Proteoglycans in cancer 💬
 1件: IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
145 Proteoglycans in cancer 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
146 Renin secretion 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
147 Rheumatoid arthritis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
148 Rheumatoid arthritis 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
149 Rheumatoid arthritis 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
150 Rheumatoid arthritis 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
151 Rheumatoid arthritis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
152 RIG-I-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
153 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
154 Salmonella infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
155 Serotonergic synapse 💬
 1件: ALOX5 💬 D00414 💬 Zileuton 3件: 85, 160, 164 💬
156 Shigellosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
157 Small cell lung cancer 💬
 1件: RARB 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
158 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
159 Systemic lupus erythematosus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
160 Systemic lupus erythematosus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
161 T cell receptor signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
162 T cell receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
163 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D07474 💬 Atorvastatin 19件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 297, 299 💬
164 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00359 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
165 Terpenoid backbone biosynthesis 💬
 1件: HMGCR 💬 D00434 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
166 TGF-beta signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
167 Th1 and Th2 cell differentiation 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
168 Th1 and Th2 cell differentiation 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
169 Th1 and Th2 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
170 Th17 cell differentiation 💬
 1件: IL17A 💬 D10071 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
171 Th17 cell differentiation 💬
 1件: IL17A 💬 D09967 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
172 Th17 cell differentiation 💬
 1件: IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
173 Th17 cell differentiation 💬
 1件: IL4R 💬 D10354 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
174 Th17 cell differentiation 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
175 Th17 cell differentiation 💬
 1件: RARA 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
176 TNF signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
177 Toll-like receptor signaling pathway 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
178 Toll-like receptor signaling pathway 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
179 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
180 Toxoplasmosis 💬
 1件: ALOX5 💬 D00414 💬 Zileuton 3件: 85, 160, 164 💬
181 Toxoplasmosis 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
182 Toxoplasmosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
183 Transcriptional misregulation in cancer 💬
 1件: CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
184 Transcriptional misregulation in cancer 💬
 1件: RARA 💬 D00348 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
185 Tuberculosis 💬
 3件: IL12A, IL12B, IL23A 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
186 Tuberculosis 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
187 Tuberculosis 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
188 Type I diabetes mellitus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
189 Type I diabetes mellitus 💬
 2件: IL12A, IL12B 💬 D09214 💬 Ustekinumab 16件: 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
190 Type I diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
191 Type II diabetes mellitus 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
192 VEGF signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
193 Viral myocarditis 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
194 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
195 Virion - Adenovirus 💬
 2件: CD80, CD86 💬 D03203 💬 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
196 Wnt signaling pathway 💬
 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D05480 💬 Pimecrolimus 1件: 160 💬
197 Yersinia infection 💬
 1件: TNF 💬 D02597 💬 Adalimumab 17件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬

先頭へ